20261013_Isofol_PM_Invitation Investor & Scientific Update
Isofol invites to an Investor & Scientific Update in Stockholm and Gothenburg on November 12 and 13, respectively
GOTHENBURG, Sweden, October 13, 2026 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) invites investors, shareholders and other stakeholders to an Investor & Scientific Update in Stockholm on November 12. The principal investigator of the company’s ongoing clinical study, Prof. Sebastian Stintzing, and pharmacology expert Prof. Frits Peters will, together with representatives from the company, provide updates on the latest developments in the development of the drug candidate arfolitixorin. An investor meeting will be held in Gothenburg on November 13 to present and discuss the key messages from the Stockholm meeting.
Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, initially conducted at the German University Hospital Charité - Universitätsmedizin Berlin. The drug candidate has the potential to fill a known treatment gap in cancer care.
Isofol invites investors to an Investor & Scientific Update in Stockholm on November 12, where the principal investigator for the company’s ongoing clinical study, Professor Sebastian Stintzing at Charité, will discuss developments in colorectal cancer, current and future treatment options, and the latest results from the ongoing study of arfolitixorin. Professor Frits Peters at the Laboratory Medical Oncology, Amsterdam UMC and the Department of Biochemistry, Medical University of Gdansk, will provide the pharmacological background regarding the study’s optimized dosing regimen and explain why it is expected to further enhance the efficacy of arfolitixorin.
The meeting will also include an open Q&A session led by analysts from ABG Sundal Collier and Redeye, as well as presentations by Dr. Roger Tell, Chief Medical Officer, and Petter Segelman Lindqvist, Chief Executive Officer. Following the meeting, there will be an opportunity to meet and speak with members of Isofol’s Board of Directors and management team.
The full agenda will be published on Isofol’s website.
Investor & Scientific Update, Stockholm
Thursday, November 12, 14:30–16:30 at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden.
Investor & Scientific Update – summary, Gothenburg
Friday, November 13, 14:30–16:30 in Isofol’s facility at Arvid Wallgrens backe 20, Gothenburg, Sweden. Company representatives will summarize the key messages and presentations from the Stockholm meeting and hold an open Q&A session.
Registration
Please register via the company’s website no later than November 2:
Please note that seating at the venues is limited. A video recording of the event in Stockholm will be available on the company’s website afterwards.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 10:45 CEST on October 13, 2026.
About Isofol
Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company’s drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world’s third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.